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1Despite advances in our understanding of genetic and envi-ronmental factors contributing to essential hypertension 
and the metabolic syndrome (which may be a confounding 
issue), the underlying pathophysiology is often unknown. Rare 
monogenic hypertensive disorders have revealed that proteins 
involved with regulation of mineralocorticoid secretion and 
activity, which ultimately affect sodium balance are key to the 
maintenance of blood pressure homeostasis.1–3 Many of these 
are remediable with glucocorticoid treatment. Conversely, 
associated diseases of metabolic syndrome (including vis-
ceral obesity, insulin resistance, and type 2 diabetes mellitus) 
involve systems modulated by glucocorticoid activity,4 but the 
mechanisms linking electrolyte homeostasis and metabolic 
control have not been investigated in parallel. We have devel-
oped a new rodent model of the syndrome of apparent min-
eralocorticoid excess (SAME; OMIM No. 218030) to study 
glucocorticoid–mineralocorticoid cross-talk in more detail.
SAME is characterized by a deficiency of the enzyme 
11β-hydroxysteroid dehydrogenase type 2 (Hsd11b2), which 
inactivates glucocorticoid hormone (cortisol and corticosterone) 
by oxidation to 11-dehydro derivatives (cortisone and 11-dehy-
drocorticosterone).5 Normally, Hsd11b2 allows aldosterone, a 
hormone that circulates at much lower concentrations than glu-
cocorticoids, to bind to the mineralocorticoid receptor. In the 
absence of Hsd11b2 activity, glucocorticoids bind inappropri-
ately to mineralocorticoid receptor evoking excess mineralo-
corticoid activity (ie, sodium and water retention and potassium 
excretion) in tissues, such as kidney, colon, and sweat glands. 
Patients with SAME also present with a suppressed renin–
angiotensin–aldosterone system, short stature, failure to thrive, 
polydipsia, polyuria, and other renal pathologies.6
Theoretically, Hsd11b2 should also limit access to glu-
cocorticoid receptors (GR). However, although there are 
precedents for Hsd11b2-mediated protection of GR in lower 
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vertebrates7 and placenta,8 GR expression is more widespread 
than Hsd11b2. More important are the potential secondary 
consequences of failure to synthesize 11-dehydro derivatives. 
Hsd11b1, (the type 1 isozyme), regenerates active glucocorti-
coid from cortisone and 11-dehydrocosticosterone at periph-
eral targets, such as liver and adipose tissues with significant 
metabolic consequences. For example, mice with transgenic 
overexpression of Hsd11b1 in adipose tissue are obese and 
hypertensive.9 It follows that in the absence of Hsd11b2, 
Hsd11b1 will also be inactive through lack of substrate, caus-
ing a syndrome of glucocorticoid insufficiency.
To study these glucocorticoid- and mineralocorticoid-
related phenotypes, we have used zinc-finger nuclease (ZFN) 
technology10,11 to generate a knockout rat model of SAME. 
ZFNs are designed to generate a specific double-strand break 
in the gene of interest. This is repaired by nonhomologous end 
joining, which is prone to errors and frequently leads to the 
insertion or deletion of nucleotides. Targeted deletions were 
introduced into exon 2 of the Hsd11b2 gene, leading to inter-
ruption of the gene product.
Hsd11b2 knockout rats demonstrate many of the symp-
toms of SAME, including reduced size, polydipsia, poly-
uria, and salt-sensitive hypertension, which were previously 
observed in an Hsd11b2 knockout mouse generated by stan-
dard gene–targeting techniques.12–17 Although rats did not 
develop the profound salt wasting and progressive loss of 
renal medulla seen in older knockout mice, significant renal 
damage was observed at 9 months of age. Hsd11b2 knockout 
rats also revealed protective effects relating to glucose han-
dling and insulin sensitivity.
Methods
Detailed methods section is available in the online-only Data 
Supplement.
Statistical Analyses
Data are presented as the mean±SEM. Variables (genotype and diet) 
were compared by performing 2-way ANOVA using Prism6. Mean 
values were compared using the Student t test. A P<0.05 was consid-
ered to be statistically significant.
Results
ZFNs were designed to bind specifically to exon 2, near to the 
sequence encoding the nicotinamide adenine dinucleotide–
binding site18 (Figure S1A in the online-only Data Supplement). 
Targeting was achieved by pronuclear microinjection of ZFN 
mRNAs into single-cell embryos (Table S1). Injection of ZFN 
mRNAs at 10 ng/µL was toxic to the cells, as pup numbers 
were dramatically reduced. Targeting was achieved using ZFN 
mRNAs at a concentration of 3.125 ng/µL. Of 48 pups born, 4 
targeted progeny were identified (Table S1) using polymerase 
chain reaction (PCR) primers designed to produce a 332-bp 
product spanning the target site (Table S2). PCR products were 
screened for mismatch and cleavage with surveyor nuclease. 
Subsequent sequencing of subcloned PCR products revealed 
the extent of insertions and deletions.
Two founders carried small deletions (1 and 16 bp), whereas 
1 carried a single base-pair insertion at the target site. Founder 
no. 6 contained multiple-targeted alleles (Figure S1B), suggest-
ing that the ZFNs remain active in the embryo beyond the 2-cell 
and 4-cell stages of cell division. Deletions of 1, 4, and 16 bp 
brought a TGA nucleotide triplet stop codon into frame (Figure 
S1B), resulting in truncation of the protein. The 123 bp deletion 
removed the 3′ end of exon 2 and the first 16 bp of intron B. If 
transcription and translation continued beyond this point, then a 
TAG nucleotide triplet stop codon would be brought into frame. 
The 332 bp deletion removed the entire second exon (extend-
ing 84 bp upstream and 37 bp downstream into the flanking 
introns), which would minimally remove the nicotinamide 
adenine dinucleotide–binding site from any translated protein 
product. All alleles were segregated in the progeny of founders 
by mating with wild-type (WT) F344IcoCrl females. Although 
preliminary phenotypic analysis indicated that at least 2 lines 
were polydipsic and polyuric, only the line carrying a 123 bp 
deletion was characterized in detail.
Phenotypic Characterization of Hsd11b2 Knockout 
Animals: Morphology
Homozygous animals were indistinguishable from littermates 
at weaning, but were significantly smaller than heterozygous 
or WT animals at 12 weeks of age. Body weights of male 
Hsd11b2−/− (Hsd2KO) animals at 14 weeks old were 13% 
lower than age-matched WT animals (276.7±4.1 [n=7] ver-
sus 319.8±6.1g [n=9]; P<0.05). Female Hsd2KO animals (12 
weeks old) were 12.5% smaller than age-matched controls 
(166.2±2.6 [n=5] versus 190.5±2.5 g [n=4]). Hsd2KO animals 
had significantly larger kidneys, adrenals, and hearts than age-
matched control animals, whereas liver and mesenteric fat 
pads were significantly smaller (Figure S2).
Kidneys of young Hsd2KO animals (9 weeks of age) 
showed no gross pathological changes. Homozygotes exhibited 
weak immunoreaction with anti-Hsd11b2 antibody, (Figure 
S3C and S3E [WT] versus S3G and S3I [Hsd2KO]). Reverse 
transcription PCR primers were therefore designed, which 
spanned all introns between exons 2 and 5, to check for any 
aberrant transcripts from possible splice variants (Table S3). 
Although transcripts were observed, there were clear signs of 
aberrant/reduced splicing of the 123-bp–deleted gene transcript 
(Figure S4). For example, using primers spanning exons 2 to 
3 (flanking the 123 bp deletion), a ≈40-bp reverse transcrip-
tion PCR product was observed rather than the predicted 147 
bp product (Figure S3A, lanes 1–4). A possible cryptic splice 
donor was identified, 2 bases upstream from the TAG stop 
codon that had been predicted to truncate the protein product. 
This would account for the reverse transcription PCR results 
and would lead to the production of a protein lacking 36 amino 
acids. Western analysis clearly demonstrated a complete lack of 
the ≈40-kD WT protein (Figure S5) suggesting that no stable 
full-length protein is made from the aberrantly spliced tran-
scripts. Hsd11b2 converts corticosterone (B) to 11- dehydrocor-
ticosterone (A) and plasma A was below detection threshold in 
homozygotes, indicating loss of Hsd11b2 activity (Figure S6).
Despite the increased kidney size, nephron counts were 
not different between genotypes (data not shown). Kidneys 
of 6-month-old null males showed subtle increases in fibrosis 
compared with controls (Figure S7). Kidney injury molecule 
1 (Kim-1) antibody staining was significantly increased, 
and affected tubules were often associated with reactive 
macrophages as shown by the Cd68 macrophage marker, 
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ED-1 staining (Figure S7). Dissection of older adults (9–12 
months) revealed clear signs of kidney damage, with mul-
tifocal accumulation of amorphous acidophilic material 
expanding the Bowman space of some glomeruli (glomerular 
sclerosis) and tubules on hematoxylin–eosin (H&E) stain-
ing (Figure S8). There was clear interstitial expansion with 
lymphoplasmacytic inflammation and chronic fibrosis. The 
arcuate artery showed fibrinoid necrosis and there were signs 
of arteritis, tubule distension, and tubule degeneration (epi-
thelial cells sloughed off). Crystalline calcium deposits were 
also observed (Figure S8).
Patients with SAME exhibit hypertrophy and hyperpla-
sia of the distal convoluted tubules. Therefore, serial sections 
of kidneys from 6-month-old rats were immunostained with 
anti-Slc12a3/NCC and anti-Hsd11b2 antibodies to distinguish 
the distal collecting tubule DCT1 from the more distal DCT2, 
connecting tubule and collecting ducts. Slc12a3/NCC stain-
ing was broadly similar between WT and Hsd2KO animals 
(Figure S3B, S3D versus S3F, S3H). Areas of colocalization 
of immunostain in serial sections (eg, Figure S3D and S3E), 
confirmed an overlap of expression along the DCT. A trend 
toward hyperplasia of DCT1 was suggested in Slc12a3/NCC-
expressing tubules (Figure S3A), which reached significance 
in Hsd11b2-expressing tubules. (No tubule hyperplasia was 
demonstrated in proximal tubules, using anti-Hsd11b1 anti-
body.) Unlike patients with SAME, only hyperplasia and not 
hypertrophy of the DCT or connecting tubule/collecting ducts 
was observed in the young adult rats.
Enlargement of the adrenal gland in Hsd2KO was unex-
pected (Figure S2). Histological examination of H&E stained 
sections (Figure S9A and S9B) suggested this was because 
of increased width of the zona fasciculata though morpho-
logical measurements suggested that cell hypertrophy was 
not involved. However, zona glomerulosa cells were margin-
ally bigger, whereas zona reticularis and medullary cells were 
smaller (Figure 1A). Expression of Hsd11b2 was confirmed 
by immunohistochemistry in the zona fasciculata and zona 
reticularis of WT but not Hsd2KO adrenals (Figure S9C–S9F).
Heart tissue sections of 6-month-old rats were stained with 
Masson Trichrome and with anti–ED-1 antibody. Multifocal 
mild subendocardial replacement fibrosis of the ventricular 
walls was observed. All homozygotes showed a mild but sig-
nificant increase in macrophage numbers (32.8±3.0 per field 
[×20 magnification] versus 22±1.3 control; P<0.05) and mild 
multifocal increased fibrosis of the papillary muscles com-
pared with controls (Figure S10). The dramatic reduction in 
mesenteric fat pads in the Hsd2KO animals was because of 
significantly reduced adipocyte size, suggesting decreased 
fat storage (Figure 1B and S9G–S9H). No sign of increased 
inflammatory cell infiltration was observed.
Blood Pressure
Older Hsd2KO animals (9–12 months of age) exhibited 
adverse effects of chronic hypertension, including pulmonary 
congestion and enlarged hearts with concentric cardiac hyper-
trophy and congested right atria. Two Hsd2KO females had 
massively enlarged mesenteric arteries with marked expan-
sion of the tunica media, suggestive of chronic active pan-
arteritis (Figure S8G–S8I).
Baseline telemetric measurements revealed that on a 0.3% 
Na diet Hsd2KO animals were severely hypertensive with 
a mean arterial blood pressure of 170.5 mm Hg (compared 
with WT–113.5 mm Hg). Change to a 0.03% Na diet reduced 
mean arterial blood pressure by almost 30 to 142.8 mm Hg 
(Figure 2A).
Metabolic Cage Analyses
On 0.3% Na diet, Hsd2KO animals were clearly polydipsic 
and polyuric (from 7 weeks of age; data not shown). Both 
urinary albumin and calcium excretion levels were signifi-
cantly higher in Hsd2KO samples than controls (Figure S11). 
This probably reflected the exposure to high blood pressure 
because both albumin and calcium levels were decreased on 
the 0.03% diet.
On 0.3% Na diet, urinary Na/K ratio was slightly higher 
in Hsd2KO animals and a significantly higher percentage of 
sodium intake was secreted by the kidney (Table), the balance 
being excreted through the gut.19,20 On transfer to 3% Na+ diet, 
increases in water intake and urine production were greater in 
Hsd2KO than in WT rats (Table). Hsd2KO rats ate less of 
the 3% Na diet and achieved a lower Na/K ratio. WT (and 
Hsd2+/−) animals maintained a normal sodium balance by 
increased urinary sodium excretion. Hsd2KO animals were 
not able to maintain an appropriate natriuretic response on 
a 3% Na diet. After 3 days on this diet, they developed diar-
rhea, urinary Na/K ratios fell, and the study was terminated.
On transfer from a 0.3% Na to a 0.03% Na diet, water 
consumption, urine production and sodium excretion dropped 
to broadly WT levels (Table). The drop in urinary Na+ and 
Na/K ratio was more acute in Hsd2KO rats than in controls 
(Figure 2B and 2C), and cumulative sodium balance in WT 
but not Hsd2KO rats was negative across the first few days 
(Figure 2D). On the 0.03% Na diet, homozygotes excreted a 
significantly lower percentage of sodium via the kidney (Table).
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Hormone Measurements
Plasma corticosterone and aldosterone levels, taken at 7:00 
am and 7:00 pm, showed expected diurnal variation21,22 on 
both the 0.3% and 0.03% Na diets, and did not vary sig-
nificantly from control levels (Figure 3A and 3B). Renin 
levels, however, were lower than WT levels at 7:00 am and 
7:00 pm on 0.3% Na diet and were significantly suppressed 
in the evening on the 0.03% Na diet (Figure 3C). Two-way 
ANOVA of aldosterone/plasma renin concentration shows 
that Hsd2KO values are ≈8-fold higher than WT (178±68.5 
versus 20.3±5.1) due entirely to the suppression of plasma 
renin concentration. Diet and time did not contribute sig-
nificantly to variation and showed no significant interactions 
with genotype.
Glucose Tolerance Test
Increases in plasma glucose in response to an oral challenge 
were similar in Hsd2KO and WT animals, but levels over-
all were lower in Hsd2KO rats, indicating that homozygotes 
were more sensitive to insulin (Figure 4A). Indeed, plasma 
insulin levels during the test were significantly lower in the 
Hsd2KO animals (Figure 4B) at all time points. Homeostasis 
model assessment measurements for fasted rats are WT: 
11.75±1.98; KO: 4.12±0.63, confirming greater insulin sen-
sitivity (P<0.005).
Discussion
We made a rat Hsd2 null model to capitalize on the phe-
notyping possibilities of this species. ZFN targeting proved 
to be an effective method for producing an allelic series—6 
deletions and 1 insertion event—in the Hsd11b2 gene. The 
optimum mRNA concentration for founder production was 
3.125 ng/µL. The majority of targeting events (4 bp or 16 bp 
deletions and 1 bp insertion) brought a TGA stop codon into 
frame in exon 2. The 2 larger deletions (123 bp and 332 bp) 
removed part or all of exon 2, respectively. Although aber-
rantly spliced transcripts were observed in the Hsd2KO ani-
mals carrying the 123 bp deletion, no enzyme activity, and 
no full-length protein on Western analysis were observed. 
This suggests that the weak immunohistochemical signal 
seen in kidney sections with anti-Hsd11b2 antibody repre-
sents nonfunctional protein.
Hsd2KO rats were born in normal Mendelian ratios and 
were not disadvantaged neonatally. Reduction in adult body 
weight was due, in part, to decreased adiposity. Nevertheless, 
kidney and heart weights were higher, possibly resulting from 
chronic exposure to high blood pressure. It is not known 
whether the fibrotic damage and mild inflammation seen in 
the hearts of Hsd2 knockouts at 6 months of age is caused 
before or because of hypertensive damage. Homozygous rats 
exhibited several signs of mineralocorticoid excess. Blood 
pressure was already high on a 0.3% Na diet and was reduced 
significantly by 0.03% Na diet. There was evidence of hypo-
kalemia (data not shown) and plasma renin was suppressed 
even despite a 0.03% Na diet.
Increased kidney size reflected hyperplasia (but not hyper-
trophy) of the DCT in young adult Hsd2KO rats. Subtle signs 
of kidney damage included Kim-1 expression and macro-
phage infiltration. Increases in interstitial cells and glomerulo-
sclerotic and fibrinoid necrotic changes were evident in older 
animals, but unlike older Hsd2KO mice, the renal medulla did 
not show overt signs of atrophy. As in human patients and the 
mouse SAME model, Hsd2KO rats exhibit overt polydipsia 
and polyuria. In mice, failure to concentrate urine has been 
attributed to reduced expression of aquaporins progressing 
in older animals to a form of nephrogenic diabetes mellitus 
insipidus23 linked to the degeneration of the renal medulla.14 
In Hsd2KO rats polyuria does not worsen with age consis-
tent with a lack of effect on renal medulla. However, although 
the polyuria is significantly worse than WT rats on a 3% Na 
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diet, there is no genotypic difference in water intake or urine 
volume on 0.03% Na diet. Given that blood pressure and uri-
nary excretion patterns of Hsd2KO and WT rats follow simi-
lar trends in relation to dietary sodium intake, it is possible 
that pressure natriuresis differences24 explain urine volume 
variation both between genotypes and in response to dietary 
manipulation.
Unlike the mouse SAME model,12 the antinatriuretic/
kaliuretic activity of apparent mineralocorticoid excess was 
not reflected in urinary Na/K ratios or increased plasma vol-
ume. Indeed Na/K was higher, not lower, in Hsd2KO rats and 
haematocrit values suggested volume contraction rather than 
expansion. Volume contraction has been noted in other models 
of steroid hormone excess and mineralocorticoid-dependent 
changes in urinary electrolyte excretion are only transient 
during adaptation from one steady state to another. Evidence 
suggests that the null rat is primed to excrete a greater pro-
portion of ingested salt through the kidney on 0.3% diet, is 
unable to adequately cope with salt load on the 3% diet, and 
is capable of rapidly shutting down kidney Na excretion on 
the 0.03% diet as blood pressure drops. These kidney adaptive 
responses may be linked to fecal sodium and potassium excre-
tion because in normal rats, colonic and renal 11βHSD2 activ-
ity are differentially expressed in response to dietary sodium 
Table.  Metabolic Analysis of WT and Hsd2KO Animals on 0.3%, 3%, and 0.03% Na Diets
Diet 0.3% Na 3% Na 0.03% Na
Genotype (n)
WT Hsd2−/− WT Hsd2−/− WT Hsd2−/−
4 5 4 5 5 5
Food intake 15.13±0.25 15.82±0.43 13.22±0.61 10.08±0.37* 13.6±0.3 13.5±0.6
Water intake 14.55±0.54 26.87±0.51** 50.73±1.61 76.38±1.92** 13.2±0.5 13.1±0.6
Urine production 4.60±0.18 16.15±0.78** 42.04±1.9 69.15±2.06** 3.4±0.2 3.8±0.3
Feces production 4.28±0.16 5.53±0.25 1.67±0.13 1.46±0.16 2.15±0.2 2.5±0.3
Urinary Na 817.2±39.6 1075.1±45.6** 17 145±2162 14 041±1943* 35.1±9.1 19.9±7.5**
Urinary K 2642.1±139.8 2042.8±204.2* 1794.3±174.4 1862.4±334.5 1151.0±44.5 1013.7±85.5
Na/K ratio 0.31±0.01 0.53±0.01* 9.56±0.54 7.54±0.39* 0.03±0.01 0.02±0.00
%Na through kidney 46.15±5.51 56.21±5.44** 99.03±4.41 107.72±8.14* 19.09±4.58 11.45±4.59**
WT indicates wild-type.
*P<0.05; **P<0.01—between WT and Hsd2KO for a given treatment.
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manipulation.19,20 In addition, there could be an autonomic 
nervous system component because small changes in plasma 
Na (2 or 3 mmol/L) can exert profound effects on the sympa-
thetic nervous system.
Predictably, dietary sodium restriction in WT rats was 
associated with increased plasma aldosterone and a marked 
increase in renin at night time.22 However, unlike SAME in 
humans and mice, plasma aldosterone was not suppressed in 
Hsd2KO rats. Moreover, zona glomerulosa cells of Hsd2KO 
rats were hypertrophied, albeit slightly, compared with WT 
cells. This was unexpected because plasma renin and potas-
sium concentrations, the main trophic factors for aldosterone 
synthesis, were both markedly reduced. The third trophic fac-
tor, adrenocorticotropic hormone, is an unlikely candidate to 
explain the lack of aldosterone suppression because diurnal 
changes in corticosterone and zona fasciculata cell size were 
unaffected by genotype and zona reticularis cells were smaller 
in Hsd2KO rats. There are, however, many other known fac-
tors (eg, dopamine, serotonin, local adrenal renin angiotensin 
system, renal clearance of aldosterone, or atrial natriuretic 
hormone) that might be involved. Given evidence of vascular 
volume contraction, it would seem likely that atrial natriuretic 
hormone is suppressed in Hsd2KO rats, thereby removing a 
tonic inhibitory effect on aldosterone synthesis25 and contribut-
ing to the aldosterone escape.
The metabolic phenotype of reduced adiposity and 
increased insulin sensitivity suggest glucocorticoid activ-
ity is reduced in Hsd2KO rats. This argues against the idea 
that Hsd11b2 activity limits access to GR in the same way 
that mineralocorticoid receptor is protected and highlights 
the importance of the isozyme, Hsd11b1, in glucocorticoid-
regulated tissues, such as the liver, pancreas, and adipose 
tissues. In the absence of Hsd11b2, there is no substrate for 
Hsd11b1 and, therefore, no local regeneration of active hor-
mone26 in tissues where glucocorticoids influence glucose 
and lipid metabolism. The lack of macrophage infiltrate in 
mesenteric fat pads reflected the favorable metabolic pheno-
type. Both improved glucose tolerance and insulin sensitivity 
in adipocytes and liver have been demonstrated in the mouse 
Hsd11b1−/− model,27,28 whereas Hsd11b1 inhibition has previ-
ously been reported29 to specifically reduce fat accretion in the 
mesenteric fat pad.
Interestingly, the adrenal does not show the hypertrophied 
phenotype of Hsd11b1 deficiency,30 presumably because 
reduced clearance of glucocorticoids by Hsd11b2 is coun-
terbalanced by reduced regeneration via Hsd11b1. This idea 
of opposing effects of Hsd11b isozymes could be extended 
to other tissues. For example, even in the kidney, where 
the SAME phenotype is paramount, it should be noted that 
Hsd11b1 is expressed in proximal tubules where GR-mediated 
effects on fluid and electrolyte balance have been described.
In summary, we have developed a rat SAME model 
exhibiting many classic characteristics of the Human SAME 
patient. In addition, the effective chronic loss of key Hsd11b1 
and Hsd11b2 activities, aldosterone escape and a protective 
metabolic profile, superimposed on salt-sensitive hyperten-
sion, provides scope for extended mechanistic characteriza-
tions afforded by this species.
Perspectives
With the advent of efficient, relatively cost-effective tech-
niques for targeting genome modifications in the rat, includ-
ing ZFNs, Talens, and the Crispr-Cas9 system, we can now 
begin to fully capitalize on the wider range of experimental 
possibilities available for this species. The rat SAME model 
presents with an intriguing and complex mix of protective 
metabolic effects superimposed on a background of chronic 
salt-sensitive hypertension, which further define the subtleties 
of Hsd11b2 loss of function in SAME.
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What Is New?
•	The rat syndrome of apparent mineralocorticoid excess model reported 
here is extraordinary because of the normal aldosterone levels seen in 
the context of apparent mineralocorticoid excess, suggesting aldoste-
rone escape. The metabolic sequelae of Hsd11b2 knockout reflect the 
concomitant effective knockout of Hsd11b1 activity.
What Is Relevant?
•	The interplay between reduced function of Hsd11b2, Hsd11b1, and aldo-
sterone could inform certain cases of essential hypertension.
Summary
The rat syndrome of apparent mineralocorticoid excess model 
presents with an intriguing and complex mix of protective metabol-
ic effects superimposed on a background of chronic, salt-sensitive 
hypertension.
Novelty and Significance
